The Future of Life Science Entrepreneurship and Investment in Europe

Invitation to a conversation with Peter Llewellyn-Davies

Entrepreneurship has shaped the last 30 years of our society:

  • Facebook redefined the way people communicate globally at zero expenses

  • Apple redefined the Music Industry and created digital assistants with tablets and phones that store all books, magazines, mails, pictures, and favorite music in one place.

  • Biontech has invented the solution for the novel Coronavirus

Dealroom.co has issued an excellent report about

A UiPath to success: Central and Eastern European startups coming of age

Usually, as it is the nature of reports, they are tech-heavy and usually focused on other tech areas than life science.

Let's shine more light on the coming of age of the European life science industry.

I am interested in the unique personal perspective on entrepreneurship in life science from experts in our community.

Speaker in this Episode:

Peter Llewellyn-Davies, CEO at Apeiron Biologics and President at Biotech Austria.

Peter has more than 25 years of professional experience as a Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc., as well as Advisory roles in companies to execute exit strategies such as Suppremol GmbH, CoreOptics GmbH, and Setron GmbH. Peter joined APEIRON Biologics in 2017.

In this recording, we will talk about the European life-science eco-system with a special focus on Biotech in Austria.

Questions we will discuss:

  • A personal view on the History of Life Science in Europe

  • Successes from Biotech Austria

  • The Future - Where is Room for Improvement in Europe in the Life Science Industry?

  • Insights into Biotech Austria

  • And much more…

Sign Up Today:

Register here

More about the Speaker:


Noteworthy Articles:

A UiPath to success: Central and Eastern European startups coming of age Our new report in partnership with Google for Startups and Atomico explores the CEE ecosystem development, current state of play, and future trends driving a €186B ecosystem. Read more…

PitchBook-NVCA Venture Monitor An explosion of mega-rounds ($100 million+) drove more than $49 billion in deal value, as the annual total surpassed $238 billion. Read more…

25 Business Moats That Helped Shape TheWorld's Most Massive Companies A business moat is a key competitive advantage that sets a company apart from its competitors. From Amazon and Tesla to Starbucks and Coinbase, here is how 25 of the world's biggest companies have built and defended their moats. Read more…


LISTEN TO THIS EPISODE OF THE LSG2G PODCAST HERE

In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.

In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, about how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.
LISTEN TO THIS EPISODE OF THE LSG2G PODCAST HERE


Support the Show:

If you enjoy the LSG2G Podcast Beginners Mind, you can help support the show by doing the following:

  • Become a Subscriber and get access to shows early or help contribute

  • Subscribe on Spotify | YouTube | and leave a comment

  • Share the show and episodes with your friends and family with this Link

  • Follow on Linkedin | Twitter |

If you are interested in sponsoring the show, please feel free to drop me an email to discuss options.


Community Partner:

These companies make the community, this newsletter, and the LSG2G Podcast possible, so go check them out and thank them for their support!

Partner Links


You are receiving the LSG2G-Letter because you either signed up or attended one of the events organized by LSG2G. Feel free to unsubscribe if you aren't finding this valuable.

Nothing in this email is intended to serve as financial advice. Do your own research.